This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SYNGR1 / Synaptogyrin-1 · IHC design guide
Design Immunohistochemistry for SYNGR1
Plan SYNGR1 paraffin IHC using high staining in cerebral cortical neuropil as a reference (HPA tissue IHC). Start catalog antibody A10148 at 2.5 μg/mL (datasheet) and compare sections using consistent fixation.
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SYNGR1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cerebral cortical neuropil (HPA tissue IHC); synaptic vesicle membrane (UniProt) | |
| Staining pattern | Selective staining in cerebral cortical neuropil (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Cerebral cortex+4 more · see all | |
| Negative control | Duodenum+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining and RNA expression show medium consistency (HPA tissue IHC) | |
| Regulation | Expression regulation not reported (UniProt) | |
| Isoform / epitope | 3 isoforms; cytoplasmic versus lumenal epitope coverage is unknown (UniProt) |
Section 1
Recommended SYNGR1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by one published chromogenic SYNGR1 IHC protocol (PMC6944231).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A10148); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-SYNGR1, 2.5 μg/mL (datasheet A10148) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SYNGR1-positive staining in neuropil of cerebral cortex (HPA tissue IHC: High). HPA tissue profile: Selective expression in neuropil. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page antigen retrieval); the paper also reports pH 9 retrieval (PMC6944231).
Section 2
What Is the Expected SYNGR1 Staining Pattern?
SYNGR1 is a four-pass membrane protein of synaptic vesicles and other cytoplasmic vesicles (UniProt O43759 topology and subcellular location). In paraffin sections, expect the strongest reported staining in cerebral cortex neuropil, with medium staining in cerebellar granular-layer cells and selected non-neural cell types (HPA tissue IHC). HPA rates the tissue profile Enhanced, while noting medium consistency between antibody staining and RNA expression (HPA reliability).
| Strong staining in cerebral cortex neuropil, with little nuclear staining. | This matches the reported High neuropil signal (HPA tissue IHC) and SYNGR1’s vesicle-membrane location (UniProt O43759 subcellular location). Read staining against tissue architecture: neuropil signal should be assessed separately from nearby cell bodies, because a strong regional signal does not establish that every cell in the region expresses SYNGR1. |
| Moderate staining in selected cells outside the cortex. | Medium staining is reported in cerebellar granular-layer cells, kidney tubular cells, lung macrophages, and glandular cells in several named tissues (HPA tissue IHC). These are plausible positives when the stained cell type matches the reference; staining of every cell throughout such a tissue would exceed the reported selective pattern (HPA tissue IHC). |
| Predominantly nuclear staining or an unexpected uniform compartmental pattern. | Treat this as discordant with the vesicle-membrane assignment (UniProt O43759 subcellular location and topology) and the selective neuropil tissue pattern (HPA tissue IHC). Recheck morphology, counterstain, and detection controls before interpreting the signal as SYNGR1; paraffin-section IHC cannot resolve individual synaptic vesicles by routine light microscopy (standard IHC practice). |
| Strong signal in a cell type reported as undetected. | For example, hippocampal glial cells and duodenal glandular cells are listed as Not detected (HPA tissue IHC). Investigate antibody cross-reactivity or endogenous detection activity as possible explanations (standard IHC practice). An unexpected positive alone cannot distinguish those causes or prove that the HPA reference applies to every specimen. |
| Diffuse stain across cells and extracellular spaces, or no stain in cortex neuropil. | Widespread diffuse signal is difficult to reconcile with selective neuropil expression (HPA tissue IHC); assess background with a no-primary control (standard IHC practice). Absent signal in a known-positive cortex section conflicts with the reported High neuropil level (HPA tissue IHC), but first check tissue preservation and the IHC workflow (standard IHC practice). |
💡Expected SYNGR1 appearanceCall a section positive when cortex neuropil shows strong, anatomically selective staining (HPA tissue IHC), consistent with vesicle-associated SYNGR1 (UniProt O43759 subcellular location); prominent nuclear or uniform pan-tissue colour is suspect (standard IHC interpretation).
| Antibody validation and reference pattern | The tissue profile is Enhanced, with medium antibody–RNA consistency (HPA reliability). CAB034277 has Enhanced IHC validation; HPA029673 has Approved IHC validation (HPA antibodies). Compare the staining pattern with the cell-type reference and include controls; these labels do not guarantee specificity in a new preparation (standard IHC practice). |
| Epitope position and membrane topology | SYNGR1 has 4 transmembrane segments, with cytoplasmic and lumenal intervals (UniProt O43759 topology). Whether a particular antibody recognizes an accessible epitope depends on its binding site and the preparation (standard IHC practice); no epitope location or target-specific retrieval effect is supplied. |
| Isoforms and processing | UniProt lists 3 isoforms, 1A, 1B, and 1C, and a single 1–233 chain without an annotated signal peptide or propeptide (UniProt O43759 isoforms and processing). The supplied evidence does not identify which isoforms an antibody detects; do not infer isoform specificity or tissue-dependent shedding from this record. |
| IF/ICC: what pattern is reported? | HPA reports supported cytosol localization in ICC-IF images from A-431, U-251MG, and U2OS (HPA subcellular). This is a cell-imaging observation, while the paraffin-section reference is selective neuropil staining (HPA tissue IHC). Use the separate IF/ICC guide for that application; the ICC observation does not establish an IHC protocol. |
| Antigen retrieval and fixation evidence | Target-specific fixation effects are not established by the supplied assay evidence. Verify with a matched IHC source before attributing a result to fixation. |
| Situation | Likely cause | Next action |
|---|---|---|
| No staining in a cerebral cortex positive control. | The result conflicts with High cortical neuropil staining (HPA tissue IHC); inadequate detection, retrieval, or tissue preservation are possible workflow causes (standard IHC practice). | Check that the positive-control section contains intact neuropil, then verify primary antibody application, retrieval, detection reagents, and counterstain using the validated IHC workflow (standard IHC practice). Avoid calling the sample negative until the control works. |
| Nuclear signal dominates the section. | A nuclear-dominant pattern conflicts with the annotated vesicle-membrane location (UniProt O43759 subcellular location). Nonspecific binding or misleading counterstain interpretation are possibilities (standard IHC practice). | Compare with a no-primary slide and inspect nuclei under the same illumination and colour settings (standard IHC practice). If nuclear colour persists independently of the primary antibody, troubleshoot the detection or counterstain steps before scoring. |
| Diffuse colour obscures the neuropil pattern. | Excess background can result from nonspecific binding, overly concentrated reagents, or incomplete washing (standard IHC practice). A uniform field is unlike HPA’s selective neuropil profile (HPA tissue IHC). | Compare a no-primary control, review blocking and washes, and titrate the IHC-validated antibody within its documented IHC conditions (standard IHC practice). Judge improvement by recovery of the anatomical pattern, rather than by colour intensity alone. |
| A nominal negative cell population stains strongly. | Duodenal glandular cells, hippocampal glia, and several other specified populations are Not detected in the reference (HPA tissue IHC). Cross-reactivity or endogenous detection activity may produce an apparent positive (standard IHC practice). | Confirm the stained cell type morphologically, compare with a no-primary control, and assess endogenous enzyme activity where relevant to the chromogen (standard IHC practice). Record any persistent discrepancy as specimen-specific until independently supported. |
| Expected positive cells stain, but the whole tissue also appears positive. | HPA reports selective neuropil expression and cell-type-specific signals (HPA tissue IHC); broad colour may reflect background or loss of spatial discrimination during detection (standard IHC practice). | Score compartments and cell types separately, review the no-primary control, and adjust antibody concentration or detection development using the documented workflow (standard IHC practice). Preserve enough counterstain to identify the reported cells without obscuring the chromogen. |
| ICC-IF appears cytosolic, while tissue IHC highlights neuropil. | These are different reported readouts: supported cytosol localization in cultured-cell ICC-IF (HPA subcellular) and High cerebral cortex neuropil staining in tissue IHC (HPA tissue IHC). | Interpret each preparation against its own HPA reference and confirm that the antibody has validation for the chosen application (HPA antibodies). Do not use the ICC-IF description as evidence that a paraffin-section retrieval or detection step should change. |
Experiment evidence
IHC & IF images showing SYNGR1 staining
A10148 · IHCImmunohistochemistry of SYNGR1 in rat brain tissue with SYNGR1 antibody at 2.5 μg/mL.
A10148 · IFImmunofluorescence of SYNGR1 in rat brain tissue with SYNGR1 antibody at 20 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000100321-SYNGR1/tissue/cerebral+cortex#imid_10097935
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000100321-SYNGR1/tissue/colon#imid_10097861
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000100321-SYNGR1/tissue/liver#imid_10097870
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000100321-SYNGR1/tissue/kidney#imid_10097855
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA029673; green = SYNGR1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA029673; green = SYNGR1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SYNGR1 IHC & IF
🧪Run cerebral cortex first and require staining in the neuropil (HPA: cerebral cortex neuropil High). Use esophageal squamous epithelium as the negative tissue (HPA: esophagus squamous epithelial cells Not detected); cells outside the neuropil on the positive slide should show only background signal (HPA: cerebral cortex neuropil High).
Positive control tissue: Cerebral cortex (Neuropil, HPA High)
Negative control tissue: Duodenum (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SYNGR1 in A-431, U-251MG, U2OS, with annotated localisation: Cytosol (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control; an isotype control matched to the primary antibody’s host species and monoclonal or polyclonal format; and SYNGR1 knockout material, if available, as a biological negative (standard IHC practice). Quench endogenous peroxidase in cerebral cortex sections before chromogenic detection (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the A10148 rat-brain caption does not state a fixative (caption: fixative not stated). Retrieval dependency is unreported; antigen retrieval should be optimized empirically for paraffin IHC, and the supplied evidence does not establish whether frozen sections or IF are easier (supplied target/application evidence). Brain lipofuscin can cause punctate autofluorescence if the tissue is examined by IF (standard IF practice).
HPA tissue IHC evidence for SYNGR1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebral cortex | Neuropil | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Breast | Glandular cells | Medium | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Duodenum | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
| Hippocampus | Glial cells | Not detected | Protein (IHC) | HPA → |
| Oral mucosa | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
| Ovary | Ovarian stroma cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SYNGR1 IHC Tips
Troubleshoot SYNGR1 staining by comparing the observed pattern with neuropil enrichment and the protein’s vesicle membrane topology (HPA tissue IHC; UniProt O43759 topology).
How should I adjust retrieval when SYNGR1 staining is weak in paraffin sections?
Start with citrate pH 6.0 heat-induced retrieval at 95–98 °C for 20 min (page retrieval setting). If staining remains weak, compare a longer citrate incubation on adjacent sections while keeping antibody concentration and detection conditions constant (standard IHC practice). SYNGR1 has 4 transmembrane segments and short lumenal loops, so epitope accessibility may vary after processing (UniProt O43759 topology); the antibody’s epitope is not supplied. Use the rat brain image at 2.5 µg/mL as product-specific tissue context (A10148 caption), and judge improvement by clearer neuropil staining rather than stronger staining everywhere (HPA: selective neuropil expression; standard IHC practice).
Could fixation explain weak or patchy SYNGR1 staining?
Target-specific fixation sensitivity is unknown because the supplied SYNGR1 tissue caption does not state a fixative (A10148 caption). For paraffin IHC, compare sections processed with documented, consistent fixation and avoid interpreting unequal processing as a biological difference (standard IHC practice). Excessive crosslinking can mask epitopes, while inadequate fixation can compromise morphology and antigen retention (standard IHC practice); neither effect has been demonstrated specifically for SYNGR1 here. Keep retrieval at citrate pH 6.0, 95–98 °C for 20 min during that comparison (page retrieval setting), then assess neuropil staining and tissue preservation together (HPA: selective neuropil expression; standard IHC practice).
What staining pattern should I expect in brain sections?
Look for a neuropil-enriched pattern: cerebral cortex neuropil is reported as high, whereas cerebellar granular-layer cells show medium staining (HPA tissue IHC). SYNGR1 is associated with synaptic and secretory vesicle membranes (UniProt O43759 subcellular annotation), making a process-rich pattern biologically plausible in chromogenic sections (HPA tissue IHC; UniProt O43759 subcellular annotation). Do not require every neuronal soma to stain, and compare the same anatomical compartment across sections rather than pooling soma and neuropil scores (HPA: selective neuropil expression; standard IHC practice). Diffuse nuclear staining or uniform staining across unrelated compartments warrants review of counterstain, antibody concentration and detection controls (UniProt O43759 topology; standard IHC practice).
Can this antibody distinguish SYNGR1 isoforms or reveal a masked epitope?
The supplied record lists 3 isoforms, 1A, 1B and 1C, but supplies no antibody epitope or isoform-specific reactivity (UniProt O43759 isoforms; supplied A10148 caption). SYNGR1 has cytoplasmic residues 1–23, 93–103 and 170–233 and lumenal residues 45–71 and 125–148 (UniProt O43759 topology). Those positions help frame accessibility questions, but a staining change after retrieval cannot identify the bound region or prove recognition of every isoform (UniProt O43759 topology; standard IHC interpretation). Obtain an epitope map or isoform-specific validation before assigning an IHC pattern to one splice form, and score the observed staining as SYNGR1 without that distinction (standard IHC practice).
How should I investigate an IF pattern that differs from chromogenic IHC?
Treat IF/ICC as a separate application: HPA reports supported cytosolic localisation in cell images, while tissue IHC reports selective neuropil staining (HPA subcellular; HPA tissue IHC). For tissue IF troubleshooting, multiplex with a marker for the expected neuronal compartment and compare spatial overlap with the neuropil pattern (HPA: selective neuropil expression; standard IF practice). Choose a fluorophore whose emission avoids prominent tissue autofluorescence, and include a secondary-only control when assessing faint signal (standard IF practice). Match permeabilisation to the antibody epitope’s membrane side: cytoplasmic regions may require access through membranes, whereas lumenal regions require access to vesicle interiors; the supplied material does not identify this antibody’s epitope (UniProt O43759 topology; standard IF practice).
How can I reduce diffuse brown staining without losing neuropil signal?
First compare a no-primary control with the stained section to identify detection-system background (standard IHC practice). For chromogenic detection, check the peroxidase block, blocking step, washes and DAB development time, changing one condition at a time (standard IHC practice). If background rises with primary antibody concentration, titrate around the documented 2.5 µg/mL rat brain imaging concentration without treating that image as a universal optimum (A10148 caption; standard IHC practice). Preserve a clear contrast between neuropil and adjacent compartments when deciding whether a change helped, since selective neuropil staining is the reported tissue pattern (HPA tissue IHC; standard IHC practice).
How should I score SYNGR1 when much of the signal is neuropil? ⚠ ANSWER MARKED FOR VERIFICATION
Define the region and anatomical compartment before scoring, because SYNGR1 tissue staining is selective in neuropil and cerebral cortex neuropil is rated high (HPA tissue IHC). For process-rich areas, measure DAB-positive area fraction or optical density per mm² of viable tissue, using identical thresholds, imaging settings and counterstain handling (HPA tissue IHC; standard IHC practice). Where distinct positive cells can be identified, report percent positive cells or an H-score separately from the neuropil measurement (standard IHC practice). Normalise each measure to its scored tissue area or eligible cell population, and exclude folds, edges and necrosis by the same predefined rule across sections (standard IHC practice).
What separates convincing SYNGR1 staining from artefact in IHC?
Convincing brain staining should include a neuropil-enriched component, consistent with high cerebral cortex neuropil staining and SYNGR1’s synaptic vesicle membrane annotation (HPA tissue IHC; UniProt O43759 subcellular annotation). A signal confined to nuclei conflicts with the supplied vesicle membrane topology, so inspect morphology, counterstain and controls before calling it positive (UniProt O43759 topology; standard IHC practice). Staining limited to section edges, folds or necrotic areas should be excluded from interpretation, and signal persisting without primary antibody suggests detection background (standard IHC practice). Medium staining in lung macrophages is reported, so a stained macrophage alone does not establish the brain-like neuropil pattern or its specificity in that tissue (HPA tissue IHC; standard IHC interpretation).
Boster reagents
Best SYNGR1 / Synaptogyrin-1 IHC Antibodies
Anti-SYNGR1 antibodies have rat brain IHC and IF images (A10148 image captions) and a human A549 ICC/IF image (A10148-1 image caption); both list Human, Mouse and Rat reactivity (catalog applications/reactivity).
Real IHC data
Anti-Synaptogyrin-1 SYNGR1 Antibody
Cat # A10148
The rendering SKU, A10148, has rat brain IHC at 2.5 μg/mL and IF at 20 μg/mL (A10148 image captions). A10148-1 has an A549 ICC/IF image, but no IHC image in the payload (A10148-1 image captions).
Which to pick: Choose A10148 for tissue IHC: it lists IHC-P and shows rat brain staining at 2.5 μg/mL; its fixative is unreported (A10148 applications; A10148 IHC image caption). For IF/ICC, A10148-1 shows A549 cell staining at 5 μg/mL, while A10148 shows rat brain IF at 20 μg/mL (A10148-1 IF image caption; A10148 IF image caption). Both list Human, Mouse and Rat reactivity, but cross-species IHC performance needs verification for the intended sample; both are rabbit antibodies with clonality unreported (catalog reactivity/host/clone; image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O43759 (SNG1_HUMAN, Synaptogyrin-1).
- Human Protein Atlas. SYNGR1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. SYNGR1 subcellular location (ICC-IF): Localized to the cytosol..
- Human Protein Atlas. SYNGR1 antibody validation summary (2 antibodies).
- The Proteome of the Dentate Terminal Zone of the Perforant Path Indicates Presynaptic Impairment in Alzheimer Disease. Molecular & cellular proteomics : MCP 2020 — PMC6944231.
- PubMed PMID:9760194 — UniProt-cited evidence.
- PubMed PMID:15461802 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SYNGR1 (Synaptogyrin-1). Expected localisation Cerebral cortical neuropil (HPA tissue IHC); synaptic vesicle membrane (UniProt). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A10148 at 2.5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Cerebral cortex (Neuropil); negative Duodenum. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A10148); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-SYNGR1, 2.5 μg/mL (datasheet A10148); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Staining and RNA expression show medium consistency (HPA tissue IHC); Isoform / epitope: 3 isoforms; cytoplasmic versus lumenal epitope coverage is unknown (UniProt); Regulation: Expression regulation not reported (UniProt). Evidence: UniProt O43759, HPA tissue IHC · Enhanced, HPA ICC-IF · cytosol., Datasheet A10148, PMC6944231. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SYNGR1/immunohistochemistry-ihc-guide.